Havrix

Havrix is an injectable vaccine that contains inactivated hepatitis A virus and aluminium hydroxide as adjuvant. It is supplied as a sterile solution for intramuscular administration. The product is prescribed in the European Union for prophylaxis against hepatitis A infection. Havrix is a prescription‑only medication that stimulates the immune system to produce protective antibodies against the hepatitis A virus. It is administered in two doses to achieve lasting immunity.

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure.

- Adults and children aged 12 months and older who require hepatitis A prophylaxis. - Travelers to regions where hepatitis A is endemic or where outbreaks have occurred. - Persons with occupational exposure to hepatitis A virus, such as laboratory workers. - Individuals with chronic liver disease who need additional protection against hepatitis A. - Close contacts of patients with confirmed hepatitis A infection.

The safety profile of Havrix includes both common, mild reactions and rare, serious adverse events.

Common: - Mild pain, redness, or swelling at the injection site that usually resolves within a few days. - Low‑grade fever lasting 24‑48 hours after vaccination. - Headache that is transient and improves without medication. - Fatigue or general malaise that may last one to two days.

Serious: - Severe allergic reaction (anaphylaxis) presenting with difficulty breathing, hives, or swelling of the face and throat. - Guillain‑Barré syndrome, a rare neurological disorder that can develop weeks after vaccination. - Persistent high fever that continues beyond 48 hours and is not responsive to antipyretics. - Seizures (rare) occurring shortly after immunization.

Before administering Havrix, healthcare providers should consider several precautionary measures to ensure safe use.

- Avoid vaccinating individuals with a known severe allergy to any vaccine component, including aluminium hydroxide. - Postpone vaccination in persons with an acute moderate or severe illness until they recover. - Use caution in patients who have previously experienced hypersensitivity reactions to other vaccines. - Assess the need for vaccination in individuals with chronic liver disease, as they may benefit from protection. - Consider deferring the vaccine in pregnant or breastfeeding women until a risk‑benefit evaluation is completed. - Observe the injection site for at least 15 minutes after administration to detect immediate allergic reactions.

Havrix generally has a low potential for drug interactions, but certain situations warrant attention.

Avoid: - Do not co‑administer with other live vaccines in the same injection site, as it may affect immune response. - Avoid simultaneous administration with immunoglobulin products intended for passive immunization against hepatitis A, which can interfere with vaccine efficacy.

Use with caution: - Concomitant use of immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may reduce antibody response; monitor serology if needed. - Patients receiving blood products or plasma derivatives should be evaluated for timing relative to vaccination. - Individuals on antipyretic or analgesic medication may experience masked fever; assess clinical status accordingly.